Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15466863 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Cole AR, et al. (2004) GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. J Biol Chem 279, 50176-80 15466863
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T509-p - CRMP-2 (human)
Orthologous residues
CRMP‑2 (human): T509‑p, CRMP‑2 iso3 (human): T614‑p, CRMP‑2 (mouse): T509‑p, CRMP‑2 (rat): T509‑p, CRMP‑2 (chicken): T509‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  293 (epithelial), SH-SY5Y (neural crest)
 Cellular systems studied:  cell lines
 Species studied:  human, rat
 Comments:  promotes neurite growth
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3B (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
CT-99021 decrease

T514-p - CRMP-2 (human)
Orthologous residues
CRMP‑2 (human): T514‑p, CRMP‑2 iso3 (human): T619‑p, CRMP‑2 (mouse): T514‑p, CRMP‑2 (rat): T514‑p, CRMP‑2 (chicken): T514‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  293 (epithelial), SH-SY5Y (neural crest)
 Cellular systems studied:  cell lines
 Species studied:  human, rat
 Comments:  promotes neurite growth
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3B (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
CT-99021 decrease

S518-p - CRMP-2 (human)
Orthologous residues
CRMP‑2 (human): S518‑p, CRMP‑2 iso3 (human): S623‑p, CRMP‑2 (mouse): S518‑p, CRMP‑2 (rat): S518‑p, CRMP‑2 (chicken): S518‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  293 (epithelial), SH-SY5Y (neural crest)
 Cellular systems studied:  cell lines
 Species studied:  human, rat
 Comments:  promotes neurite growth
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3B (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
CT-99021 decrease

S522-p - CRMP-2 (human)
Orthologous residues
CRMP‑2 (human): S522‑p, CRMP‑2 iso3 (human): S627‑p, CRMP‑2 (mouse): S522‑p, CRMP‑2 (rat): S522‑p, CRMP‑2 (chicken): S522‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Relevant cell lines - cell types - tissues:  293 (epithelial), SH-SY5Y (neural crest)
 Cellular systems studied:  cell lines
 Species studied:  human, rat
 Comments:  promotes further phosphorylations at T509, T514 and S518

T509-p - CRMP-4 (human)
Orthologous residues
CRMP‑4 (human): T509‑p, CRMP‑4 iso3 (human): T623‑p, CRMP‑4 (mouse): T509‑p, CRMP‑4 iso3 (mouse): , CRMP‑4 (rat): T509‑p, CRMP‑4 iso2 (rat): T622‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3B (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
CT-99021 decrease

T514-p - CRMP-4 (human)
Orthologous residues
CRMP‑4 (human): T514‑p, CRMP‑4 iso3 (human): T628‑p, CRMP‑4 (mouse): T514‑p, CRMP‑4 iso3 (mouse): , CRMP‑4 (rat): T514‑p, CRMP‑4 iso2 (rat): T627‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3B (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
CT-99021 decrease

S518-p - CRMP-4 (human)
Orthologous residues
CRMP‑4 (human): S518‑p, CRMP‑4 iso3 (human): S632‑p, CRMP‑4 (mouse): S518‑p, CRMP‑4 iso3 (mouse): , CRMP‑4 (rat): S518‑p, CRMP‑4 iso2 (rat): S631‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3B (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
CT-99021 decrease

S522-p - CRMP-4 (human)
Orthologous residues
CRMP‑4 (human): S522‑p, CRMP‑4 iso3 (human): S636‑p, CRMP‑4 (mouse): S522‑p, CRMP‑4 iso3 (mouse): , CRMP‑4 (rat): S522‑p, CRMP‑4 iso2 (rat): S635‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE DYRK2 (human)

T509-p - CRMP-2 (rat)
Orthologous residues
CRMP‑2 (human): T509‑p, CRMP‑2 iso3 (human): T614‑p, CRMP‑2 (mouse): T509‑p, CRMP‑2 (rat): T509‑p, CRMP‑2 (chicken): T509‑p
Characterization
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)

T514-p - CRMP-2 (rat)
Orthologous residues
CRMP‑2 (human): T514‑p, CRMP‑2 iso3 (human): T619‑p, CRMP‑2 (mouse): T514‑p, CRMP‑2 (rat): T514‑p, CRMP‑2 (chicken): T514‑p
Characterization
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)

S518-p - CRMP-2 (rat)
Orthologous residues
CRMP‑2 (human): S518‑p, CRMP‑2 iso3 (human): S623‑p, CRMP‑2 (mouse): S518‑p, CRMP‑2 (rat): S518‑p, CRMP‑2 (chicken): S518‑p
Characterization
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)

S522-p - CRMP-2 (rat)
Orthologous residues
CRMP‑2 (human): S522‑p, CRMP‑2 iso3 (human): S627‑p, CRMP‑2 (mouse): S522‑p, CRMP‑2 (rat): S522‑p, CRMP‑2 (chicken): S522‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Cellular systems studied:  tissue
 Species studied:  rat

T509-p - CRMP-4 (rat)
Orthologous residues
CRMP‑4 (human): T509‑p, CRMP‑4 iso3 (human): T623‑p, CRMP‑4 (mouse): T509‑p, CRMP‑4 iso3 (mouse): , CRMP‑4 (rat): T509‑p, CRMP‑4 iso2 (rat): T622‑p
Characterization
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)

T514-p - CRMP-4 (rat)
Orthologous residues
CRMP‑4 (human): T514‑p, CRMP‑4 iso3 (human): T628‑p, CRMP‑4 (mouse): T514‑p, CRMP‑4 iso3 (mouse): , CRMP‑4 (rat): T514‑p, CRMP‑4 iso2 (rat): T627‑p
Characterization
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)

S518-p - CRMP-4 (rat)
Orthologous residues
CRMP‑4 (human): S518‑p, CRMP‑4 iso3 (human): S632‑p, CRMP‑4 (mouse): S518‑p, CRMP‑4 iso3 (mouse): , CRMP‑4 (rat): S518‑p, CRMP‑4 iso2 (rat): S631‑p
Characterization
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)

S522-p - CRMP-4 (rat)
Orthologous residues
CRMP‑4 (human): S522‑p, CRMP‑4 iso3 (human): S636‑p, CRMP‑4 (mouse): S522‑p, CRMP‑4 iso3 (mouse): , CRMP‑4 (rat): S522‑p, CRMP‑4 iso2 (rat): S635‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Cellular systems studied:  tissue
 Species studied:  rat


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.